Logo image of ALDX

ALDEYRA THERAPEUTICS INC (ALDX) Stock Fundamental Analysis

NASDAQ:ALDX - Nasdaq - US01438T1060 - Common Stock - Currency: USD

5.53  +0.17 (+3.17%)

After market: 5.42 -0.11 (-1.99%)

Fundamental Rating

1

Overall ALDX gets a fundamental rating of 1 out of 10. We evaluated ALDX against 556 industry peers in the Biotechnology industry. ALDX has a bad profitability rating. Also its financial health evaluation is rather negative. ALDX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALDX has reported negative net income.
ALDX had a negative operating cash flow in the past year.
In the past 5 years ALDX always reported negative net income.
ALDX had a negative operating cash flow in each of the past 5 years.
ALDX Yearly Net Income VS EBIT VS OCF VS FCFALDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

ALDX's Return On Assets of -61.91% is on the low side compared to the rest of the industry. ALDX is outperformed by 60.07% of its industry peers.
Looking at the Return On Equity, with a value of -90.72%, ALDX is in line with its industry, outperforming 48.38% of the companies in the same industry.
Industry RankSector Rank
ROA -61.91%
ROE -90.72%
ROIC N/A
ROA(3y)-37.64%
ROA(5y)-36.54%
ROE(3y)-50.36%
ROE(5y)-48.45%
ROIC(3y)N/A
ROIC(5y)N/A
ALDX Yearly ROA, ROE, ROICALDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

ALDX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALDX Yearly Profit, Operating, Gross MarginsALDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALDX has more shares outstanding
Compared to 5 years ago, ALDX has more shares outstanding
ALDX has a worse debt/assets ratio than last year.
ALDX Yearly Shares OutstandingALDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ALDX Yearly Total Debt VS Total AssetsALDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -1.56, we must say that ALDX is in the distress zone and has some risk of bankruptcy.
ALDX has a Altman-Z score (-1.56) which is comparable to the rest of the industry.
ALDX has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.24, ALDX is doing worse than 70.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Altman-Z -1.56
ROIC/WACCN/A
WACCN/A
ALDX Yearly LT Debt VS Equity VS FCFALDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 6.49 indicates that ALDX has no problem at all paying its short term obligations.
ALDX has a better Current ratio (6.49) than 63.49% of its industry peers.
ALDX has a Quick Ratio of 6.49. This indicates that ALDX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ALDX (6.49) is better than 63.85% of its industry peers.
Industry RankSector Rank
Current Ratio 6.49
Quick Ratio 6.49
ALDX Yearly Current Assets VS Current LiabilitesALDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ALDX have decreased strongly by -90.20% in the last year.
EPS 1Y (TTM)-90.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ALDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.14% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y42.85%
EPS Next 2Y18%
EPS Next 3Y35.61%
EPS Next 5Y26.14%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALDX Yearly Revenue VS EstimatesALDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2023 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
ALDX Yearly EPS VS EstimatesALDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALDX. In the last year negative earnings were reported.
Also next year ALDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALDX Price Earnings VS Forward Price EarningsALDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALDX Per share dataALDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ALDX's earnings are expected to grow with 35.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18%
EPS Next 3Y35.61%

More info and screens

0

5. Dividend

5.1 Amount

ALDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALDEYRA THERAPEUTICS INC

NASDAQ:ALDX (7/23/2025, 4:30:01 PM)

After market: 5.42 -0.11 (-1.99%)

5.53

+0.17 (+3.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)07-30 2025-07-30
Inst Owners48%
Inst Owner Change0.75%
Ins Owners2.98%
Ins Owner Change0%
Market Cap331.25M
Analysts86.67
Price Target8.84 (59.86%)
Short Float %8.4%
Short Ratio3.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.48%
Min EPS beat(2)-17.52%
Max EPS beat(2)40.48%
EPS beat(4)2
Avg EPS beat(4)-17.48%
Min EPS beat(4)-93.66%
Max EPS beat(4)40.48%
EPS beat(8)5
Avg EPS beat(8)5.65%
EPS beat(12)9
Avg EPS beat(12)9.97%
EPS beat(16)11
Avg EPS beat(16)7.59%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.6%
PT rev (3m)-15.74%
EPS NQ rev (1m)-454.86%
EPS NQ rev (3m)-149.95%
EPS NY rev (1m)25.65%
EPS NY rev (3m)-30.73%
Revenue NQ rev (1m)100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-8.47%
Revenue NY rev (3m)-52.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.21
P/tB 5.21
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS0
BVpS1.06
TBVpS1.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -61.91%
ROE -90.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.64%
ROA(5y)-36.54%
ROE(3y)-50.36%
ROE(5y)-48.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.49
Quick Ratio 6.49
Altman-Z -1.56
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.43%
EPS Next Y42.85%
EPS Next 2Y18%
EPS Next 3Y35.61%
EPS Next 5Y26.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-72.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.1%
OCF growth 3YN/A
OCF growth 5YN/A